Literature DB >> 32924186

The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: A comparative, retrospective, explorative statistical analysis of 4,484 patients in a real-world cohort.

C Zeidler1, M P Pereira1, M Dugas2, M Augustin3, M Storck2, V Weyer-Elberich4, G Schneider5, S Ständer1.   

Abstract

BACKGROUND: Chronic prurigo (CPG) is known as a high burdensome disease characterized by severe pruritus and multiple pruriginous lesions. Interestingly, the disease-specific burden is not well established and there are no data which compare the impact of CPG with chronic pruritus (CP) on non-lesional skin (CP-NL).
OBJECTIVES: To address this issue, we analysed datasets from 4484 patients with either CPG or CP-NL.
METHODS: Demographic medical data and additional information collected by validated patient reported outcome tools were analysed. The visual analogue scale and numerical rating scale (NRS) were used for assessing the pruritus intensity, the ItchyQoL for patients' quality of life, the Hospital Anxiety and Depression Scale and the Patient Needs Questionnaire' as a part of Patient Benefit Index for Pruritus for measuring the importance of 27 patient needs in terms of treatment goals. The Neuroderm questionnaire was used to assess the history of pruritus characteristics and the impact on sleep.
RESULTS: Patients with CPG suffered longer and with a higher intensity from pruritus [NRS worst the last 24 h, CPG 6.0 (4.0;8.0) vs. CP-NL 3.0 (5.0;7.0), P < 0.001]. In them, pruritus occurred more often and the whole day and night which led to more loss in sleeping hours [CPG 3.0 h (2.0;4.0) vs. CP-NL 2.0 h (1.0;4.0), P < 0.001]. Patients with CPG showed higher scores for depression [HADS-D, CPG 6.0 (3.0;10.0) vs. CP-NL 5.0 (2.0;8.0), P < 0.001], more impaired quality of life [ItchyQol; CPG: 72.6 (61.6;83.6) vs. CP-NL 59.4 (48.4;70.4), P < 0.001] and higher weighted needs in the predefined treatment goals. DISCUSSION: Not only the presence of severe pruritus and pruriginous lesions but also sleep disorders and other mental symptoms may contribute to a higher burden in patients with CPG when compared with patients with CP-NL.
© 2020 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2020        PMID: 32924186     DOI: 10.1111/jdv.16929

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  4 in total

Review 1.  [Update on the treatment of chronic prurigo].

Authors:  Claudia Zeidler; Manuel Pedro Pereira; Sonja Ständer
Journal:  Dermatologie (Heidelb)       Date:  2022-07-12

2.  A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States.

Authors:  Shannon Wongvibulsin; Nishadh Sutaria; Kyle A Williams; Amy H Huang; Justin Choi; Youkyung Sophie Roh; Michael Hong; Davis Kelley; Vartan Pahalyants; William Murphy; Martin Prince Alphonse; Pegah Bakhshi; Anant Walia; Yevgeniy R Semenov; Shawn G Kwatra
Journal:  J Invest Dermatol       Date:  2021-04-03       Impact factor: 7.590

Review 3.  Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.

Authors:  Anthony Bewley; Bernard Homey; Andrew Pink
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-20

4.  Itch in Adult Population with Type 2 Diabetes Mellitus: Clinical Profile, Pathogenesis and Disease-Related Burden in a Cross-Sectional Study.

Authors:  Aleksandra A Stefaniak; Piotr K Krajewski; Dorota Bednarska-Chabowska; Marek Bolanowski; Grzegorz Mazur; Jacek C Szepietowski
Journal:  Biology (Basel)       Date:  2021-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.